Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab plus immobilisation for acute Charcot neuropathic osteoarthropathy
ACTRN12617000937314Phase 2Completed
- Sponsor
- Garvan Institute of Medical Research
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of denosumab in Charcot neuroarthropathy (CN), sponsored by Garvan Institute of Medical Research. Started May 2018; status: completed.
02
Drugs
denosumab
03
Conditions
Charcot neuroarthropathy (CN)
Beyond the preview
Go deeper on ACTRN12617000937314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000937314.